You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Poster Listings<br />
Session 82 CROI <strong>2013</strong><br />
392� ��������������������������������������������������������<br />
�����������������������������������������������������<br />
����������������������������������������<br />
Christine Katlama* 1 , O Launay2 , R Ho Tsong Fang3 , H Bodilis2 , R Calin1 ,<br />
B Autran1 , S Gharakhanian4 , V Vieillard5 , J Crouzet3 , and P Debre6 1 2 Pitie-Salpetriere Hosp, Paris, France;; Cochin Hosp and INSERM<br />
CIC BT505, Paris, France;; 3InnaVirVax, Evry, France;; 4InnaVirVax, Cambridge, MA, US;; 5INSERM UMR S945, Paris, France;; and 6 404� ������������������������������������������������<br />
Disorders among Adults on cART and Suppressed Plasma<br />
Viral Load: Prospective Results from the Ontario HIV<br />
Treatment Network Cohort Study<br />
Sean Rourke*<br />
Univ<br />
Pierre and Marie Curie, Paris-6 Univ, France<br />
1,2,3 , J Gill4 , T Bekele1 , A Carvalhal2,3 , J McCombe5 ,<br />
A Rachlis2 , M Atkinson1 , C Kovacs2 , T Marcotte6 , S Letendre6 ,<br />
and OCS Cohort Study<br />
1 2 Ontario HIV Treatment Network, Toronto, Canada;; Univ of Toronto,<br />
Canada;; 3St Michael�s Hosp, Toronto, Canada;; 4Univ of Alberta, Calgary,<br />
Canada;; 5Univ of Alberta, Edmonton, Canada;; and 6Univ of California,<br />
San Diego, US<br />
393� ������������������������������������<br />
Gloria Martrus* 1 , M Nevot 1 , B Clotet 1,2 , and MA Martinez 1<br />
1 Inst de Investigacio del Sida IrsiCaixa, Badalona, Spain and 2 Lluita<br />
contra la SIDA Fndn, Hosp Univ Germans Trias i Pujol, Badalona, Spain<br />
c Wednesday, 2:30-4 pm; Hall B2<br />
Session 83–Poster Abstracts<br />
Gene and Adoptive Immunotherapy<br />
394 HIV Gene Therapy: HIV-1 pol���������������������������<br />
Nucleases Targeting HIV-1 Provirus in Latent Cells<br />
Cheol-Hee Yoon*, SS Kim, SY Park, O-K Kwon, H-Y Kim, D-H Jang,<br />
and B-S Choi<br />
Korea Natl Inst of Hlth, Osong, Chungbuk, South Korea<br />
395 Promoter Targeting Small RNA Suppresses HIV-1 Infection<br />
in vivo<br />
Kazuo Suzuki* 1 , S Hattori 2 , K Marks 1 , C Ahlenstiel 1 , M Millington 3 ,<br />
M Boyd 3 , G Symonds 3 , D Cooper 1 , S Okada 2 , and A Kelleher 1<br />
1 The Kirby Inst, Sydney, Australia;; 2 Ctr for AIDS Res, Kumamoto, Japan;;<br />
and 3 Calimmune Inc, Sydney, Australia<br />
396 T Cell Receptor Transfer for Boosting HIV-1-specific T Cell<br />
Immunity in HIV-1 + Patients<br />
Christiane Mummert* 1 , C Hofmann 1,2 , A Huckelhoven 1 ,<br />
S Muller-Schmucker 1 , J Dorrie 1 , N Schaft 1 , S Bergmann 1 , E Harrer 1 ,<br />
and T Harrer 1<br />
1 Univ Hosp Erlangen, Friedrich-Alexander Univ, Germany and 2 Univ of<br />
California, Los Angeles, US<br />
c Monday, 2:30-4 pm; Hall B2<br />
Session 84–Poster Abstracts<br />
Progressive Multifocal Leukoencephalopathy<br />
and Other Central Nervous System Infections<br />
398 Polymorphisms in Toll-like Receptor Genes Increase<br />
Neurosyphilis Risk<br />
Christina Marra*, S Sahi, L Tantalo, E Ho, T Jones, S Dunaway, and T Hawn<br />
Univ of Washington, Seattle, US<br />
399 No Benefit of Mitarzapine Add-on to ART in HIV + Patients<br />
with Progressive Multifocal Leukoencephalopathy<br />
Ana Canestri*, K Protopapas, A-A Mazet, J-P Brosseau, Y Taoufik,<br />
J-F Delfraissy, and J Gasnault<br />
Bicetre Hosp, Le Krmlin-Bicetre, France<br />
34 � 20th Conference on Retroviruses and Opportunistic Infections<br />
405 Central Nervous System Penetration Effectiveness Score Better<br />
Correlates with Cognitive Performance of HIV + Patients after<br />
��������������������������������������������������<br />
Massimiliano Fabbiani* 1 , P Grima 1,2 , B Milanini 1 , A Mondi 1 ,<br />
M Colafigli 1 , R Gagliardini 1 , R Cauda 1 , MC Silveri 1 , A De Luca 1,3 ,<br />
and S Di Giambenedetto 1<br />
1 Catholic Univ of the Sacred Heart, Rome, Italy;; 2 S Caterina Novella<br />
Hosp, Galatina, Italy;; and 3 Siena Univ Hosp, Italy<br />
406� ���������������������������������������������������<br />
a Higher Rate or a Different Pattern of Neurocognitive<br />
Impairment than Triple Drug Therapy<br />
Ignacio Perez-Valero* 1 , A Gonzalez-Baeza 1 , M Estebanez 1 ,<br />
N Stella-Ascariz 1 , J Mingorance 1 , C Bayon 1 , M Lagarde 2 , F Pulido 2 ,<br />
A Borobia 1 , J Arribas 1 , and PICASSO Study Group<br />
1 Hosp Univ La Paz, IdiPaz, Madrid, Spain and 2 Hosp Univ 12 de Octubre,<br />
i+12, Madrid, Spain<br />
c Monday, 2:30-4 pm; Hall B2<br />
Session 86–Poster Abstracts<br />
ART, Neurocognitive Outcomes, and New Central<br />
Nervous System-targeted Therapies<br />
407 Long-term Efavirenz Use Is Associated with Worse<br />
����������������������������<br />
Scott Letendre* 1 , F Vaida 1 , D Croteau 1 , D Clifford 2 , A Collier 3 , B Gelman 4 ,<br />
J McArthur 5 , D Simpson 6 , R Heaton 1 , I Grant 1 , and CHARTER Group<br />
1 Univ of California, San Diego, US;; 2 Washington Univ, St Louis, MO, US;;<br />
3 Univ of Washington, Seattle, US;; 4 Univ of Texas Med Branch, Galveston,<br />
US;; 5 Johns Hopkins Univ, Baltimore, MD, US;; and 6 Mt Sinai Sch of Med,<br />
New York, NY, US<br />
408 Gold Nanoparticles to Improve Drug Delivery<br />
to the Central Nervous System<br />
Carolina Garrido* 1 , N Dahl 1 , C Simpson 2 , J Bresee 2 , D Feldheim 2 ,<br />
C Melander 3 , and D Margolis 1<br />
1 Univ of North Carolina at Chapel Hill, US;; 2 Univ of Colorado, Boulder,<br />
US;; and 3 North Carolina State Univ, Raleigh, US<br />
409 Symptoms of Autonomic Dysfunction in HIV + Patients<br />
����������������������<br />
Dominic Chow* 1 , K Sullivan 1 , D Sletten 2 , M Kocher 1 , R Romine 1 ,<br />
B Nakamoto 1,3 , T Umaki 1 , K Kallianpur 1 , C Shikuma 1 , and P Low 2<br />
1 Univ of Hawaii at Manoa, Honolulu, US;; 2 Mayo Clin, Rochester, MN,<br />
US;; and 3 Straub Med Ctr, Honolulu, HI, US<br />
400 Clonal Immortalized Human Glial Cell Lines Support<br />
Varying Levels of JC Virus Infection Due to Differences in<br />
Cellular Gene Expression<br />
Michael Ferenczy*, K Johnson, and E Major<br />
Natl Inst of Neurological Disorders and Stroke, NIH, Bethesda, MD, US<br />
c Monday, 2:30-4 pm; Hall B2<br />
Session 85–Poster Abstracts<br />
Central Nervous System Penetration, ART<br />
Intensification, and Cerebrospinal Fluid Escape<br />
401� ������������������������������������������������������<br />
�������������������������<br />
Scott Letendre* 1 , D McClernon2 , R Deutsch1 , D Cookson1 , M Cherner1 ,<br />
M Crescini1 , I Grant1 , and R Ellis1 410� �����������������������������������������������<br />
+<br />
������������������������������������������������<br />
�������������������������������������������������<br />
Atazanavir<br />
Kevin Robertson*<br />
1 2 Univ of California, San Diego, US and bioMONTR, Research Triangle<br />
Park, NC, US<br />
1 , P Maruff2 , D Wohl1 , L Bhatti3 , C Small4 ,<br />
H Edelstein5 , H Zhao6 , D Margolis6 , L Ross6 , M Shaefer7 ,<br />
for ASSURE EPZ113734 Study Team<br />
1 2 Univ of North Carolina at Chapel Hill, US;; Cogstate Ltd, Melbourne,<br />
Australia;; 3AIDS HlthCare Fndn, Beverly Hills, CA, US;; 4New York<br />
Med Coll, Vahalla, US;; 5Alameda County Med Ctr, Oakland, CA, US;;<br />
6 7 GlaxoSmithKline, Research Triangle Park, NC, US;; and ViiV HlthCare,<br />
Research Triangle Park, NC, US<br />
411 Impact of Minocycline on Markers of Oxidative Stress<br />
+ ��������������������������<br />
Individuals with Cognitive<br />
Impairment<br />
Ned Sacktor* 1 , S Miyahara 2 , S Evans 2 , G Schifitto 3 , B Cohen 4 ,<br />
N Haughey 1 , D Graham 1 , A Nath 5 , D Clifford 6 , and AACTG A5235 Team<br />
1 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; 2 Harvard Sch of<br />
402� ������������������������������������������������������<br />
�����������������������������������������������������������<br />
the Central Nervous System HIV ART Effects Research and<br />
���������������������������������������������<br />
Ignacio Perez-Valero* 1,2 , S Letendre2 , R Deutsch2 , R Heaton2 ,<br />
D Clifford3 , J McArthur4 , S Morgello5 , B Gelman6 , A Collier7 , I Grant2 ,<br />
and CHARTER and HNRP Study Groups<br />
1 2 Hosp Univ La Paz, Madrid, Spain;; Univ of California, San Diego, US;;<br />
3 4 Washington Univ Sch of Med, St Louis, MO, US;; Johns Hopkins Univ<br />
Sch of Med, Baltimore, MD, US;; 5 Publ Hlth, Boston, MA, US;;<br />
Mt Sinai Hosp, New York, NY, US;;<br />
6 7 Univ of Texas, Galveston, US;; and Univ of Washington, US<br />
403 Maraviroc Intensification in Virally Suppressed HIV<br />
�����������������������������������������������������<br />
Performance and Declines in Immune Activation<br />
Lishomwa Ndhlovu*, T Umaki, G Chew, M Agsalda, K Amina,<br />
N Hanks, B Nakamoto, J Barbour, B Shiramizu, and C Shikuma<br />
Univ of Hawaii, Manoa, US<br />
3Univ of Rochester, NY, US;; 4Northwestern Univ, Chicago, IL, US;; 5NIH, Bethesda, MD, US;; and 6Washington Univ<br />
Sch of Med, St Louis, MO, US<br />
412� ����������������������������������������������<br />
HIV-1 + �������������������������������������������<br />
Brain Barrier Model<br />
A McFarren1 , Dina Tsukrov* 2 , E Eugenin3 , A Morgenstern4 ,<br />
F Bruchertseifer4 , S Zolla-Pazner5,6 , M Gorny5 , A Casadevall2 , J Berman2 ,<br />
and E Dadachova2 1 2 Children�s Hosp at Montefiore, Bronx, NY, US;; Albert Einstein Coll of<br />
Med, Bronx, NY, US;; 3Univ of Med and Dentistry of New Jersey, Newark,<br />
US;; 4European Commission, Joint Res Ctr, Inst for Transuranium<br />
Elemens, Karlsruhe, Germany;; 5New York Univ, NY, US;; and 6VAMC, NY, US
Change language